INTRODUCTION {#s1}
============

Intellectual disability (ID) is present in 3% of children ([@YANGMCS000562C21]; [@YANGMCS000562C30]; [@YANGMCS000562C18]). Up to 50% of moderate-to-severe ID cases are due to genetic causes ([@YANGMCS000562C17]). Cytogenetically detectable chromosome aberrations account for almost 15% of cases ([@YANGMCS000562C14]). X-linked genetic defects are estimated to account for ∼10% of males with ID ([@YANGMCS000562C26]) and associated with more than 100 X-linked genes ([@YANGMCS000562C19]). Autosomal-dominant de novo mutations have been found as an important cause of ID in sporadic patients and have a low recurrence risk ([@YANGMCS000562C33]), whereas the role of inherited variants in unaffected parents is less well understood. However, autosomal-recessive ID has a high recurrence risk and is the most common type of ID in consanguineous families ([@YANGMCS000562C19]), although only approximately 30 loci and 10 genes have been identified to date ([@YANGMCS000562C1]). During the past decade, significant progress has been made to elucidate the genetic causes of ID. However, up to 60% of individuals with ID still do not have an identified etiology ([@YANGMCS000562C24]). The FORGE (Finding of Rare Disease Genes) Canada Consortium project has identified disease-causing variants for 146 rare disorders including ID ([@YANGMCS000562C4]). The Deciphering Developmental Disorders (DDD) study is also trying to identify the genetic causes for ID and other related developmental disorders and has recruited more than 12,600 families from the United Kingdom and Ireland for genomic analyses.

Genetic evaluation of ID routinely includes a chromosomal analysis/microarray and fragile X testing ([@YANGMCS000562C18]; [@YANGMCS000562C10]). If this initial diagnostic workup is unrevealing and if there are no specific clinical features to suggest a diagnosis, whole-exome sequencing (WES) is increasingly utilized as the next diagnostic test because of the tremendous genetic heterogeneity and incomplete knowledge of all the genes causing ID ([@YANGMCS000562C36], [@YANGMCS000562C37]), The yield of WES for patients with ID is 27%--33% in large clinical series ([@YANGMCS000562C36], [@YANGMCS000562C37]).

Here we describe novel truncating de novo variants in the *AHDC1* gene associated with ID, identified using WES. *AHDC1*, located on Chromosome 1p36.11, encodes the 1603 amino acid protein AT-hook DNA-binding motif--containing protein 1. *AHDC1* has previously been implicated as a rare cause of ID ([@YANGMCS000562C34]), and all five published variants are in the coding exon. Four de novo truncating mutations are associated with syndromic expressive language delay, hypotonia, and sleep apnea ([@YANGMCS000562C34]). A de novo missense variant was identified in 1 out of 53 sporadic cases of schizophrenia by exome sequencing ([@YANGMCS000562C11]). Recently, a de novo balanced translocation with a breakpoint in *AHDC1* intron 1 that disrupts the 5′ untranslated region of *AHDC1* was identified in a 5-yr-old boy with developmental delay and ID ([@YANGMCS000562C23]). To better understand the association of *AHDC1* with ID and characterize the clinical phenotype of this new syndrome, we report our findings of de novo variants in seven patients from unrelated families with a similar clinical phenotype of severe intellectual disability or neurodevelopmental delay.

RESULTS {#s2}
=======

Exome sequencing was performed on 2157 cases with ID or developmental delay. From these cases, there were seven proband-parent trios with de novo *AHDC1* variants. These seven cases produced an average of ∼9.5 Gb of sequence per sample. Mean coverage of captured regions was ∼115× per sample, with \>97% covered with at least 10× coverage, an average of \>92% of base call quality of Q30 or greater, and an overall average mean quality score of \>Q35 (Supplemental Table 1). Initial filtering identified 271 genes (382 unique sequence changes) of interest across the seven families when considering all possible modes of inheritance. After manual filtering of variants with a minor allele frequency of \>1% in reference populations, known disease association, pattern of inheritance, and similarity of clinical phenotype, there was one common gene of interest. In each case *AHDC1* was the leading candidate because there was a novel, de novo loss of function variant, and loss of function alleles were absent from any public population database (6000 individuals of European and African American ancestry from the NHLBI Exome Variant Server), the Database of Single Nucleotide Polymorphisms (dbSNP), as well as our internal database including more than 6000 exomes of reportedly unaffected individuals. Only one nonsense variant p.Arg925Ter, located at Chr1: 27875854 G\>A, has been seen in 1 out of 65,748 alleles in Exome Aggregation Consortium (ExAC), but with a low GQ score of ∼40, suggesting that this may not be present. Other variants in other genes were eliminated from consideration because there was a single variant in a gene observed in asymptomatic parents or because it was de novo but not predicted to alter protein function.

All seven de novo *AHDC1* variants are either novel frameshift or nonsense variants that are predicted to result in loss of protein function ([Table 1](#YANGMCS000562TB1){ref-type="table"}). The seven patients from unrelated families range in age from 2 to 16 yr and have multiple neurobehavioral manifestations. All have significant developmental delay or intellectual disability and are either nonverbal or had limited ability for verbal expressive language ([Table 1](#YANGMCS000562TB1){ref-type="table"}). Exact developmental quotient/intelligence quotients were not consistently determined with the same instruments, but the degree of impairment ranged from moderate to severe, based on standardized age appropriate measures of intelligence. All of the patients demonstrate problems with muscle tone and global developmental delays, with the age at walking ranging from 20 mo to 4 yr 9 mo. Five of the patients have ataxia. The majority of the patients have behavioral issues. Two patients have autism (based on clinical diagnosis using DSM IV or V criteria), two have self-injurious behavior, one is impulsive, one is aggressive, and one patient is described as being very affectionate. Four of the children have problems with sleep: one with sleep apnea, one a "restless sleeper," one with trouble staying asleep, and another with trouble falling and staying asleep. One patient had two seizures that were not captured on EEG and another had an abnormal EEG with epileptiform activity. MRIs of the brain were abnormal in five patients, three of whom had a small or thin corpus callosum.

###### 

Clinical features of individuals with *AHDC1* de novo predicted pathogenic variants

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                       Age                                 Gender   Variant                De novo/inherited   Developmental delay   Cognitive delay  Age at walking           Current speech                                           OFC (%)   Hypotonia   Dysmorphic  Growth or feeding issues   Brain abnormality   Other neurobehavioral problems                                                                                       Other
  -------------------------------------------------------------------- ------------------------------------------------------------------- -------- --------------------- ------------------- --------------------- ----------------- ------------------------ ------------------------------------------------------- --------- ----------- ------------ -------------------------- ------------------- -------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------
  Patient 1                                                                                           2 yr                                 M        c.1945delG\                 De novo                \+                  N/A        No independent walking   No verbal speech                                           96         \+           \+      \+                         −                   ASD                                                                                                                  Omphalocele, cryptorchidism, exotropia, sleep apnea
                                                                                                                                                    p.A649Pfs\*83                                                                                                                                                                                                                                                                                                                                                             

  Short stature (1%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Patient 2                                                                                           7 yr                                 F        c.2529\_ 2545del17\         De novo                \+                  \+         3 yr 10 mo               2--3 word sentences                                        85         \+           \+      \+                         \+                  Cerebral palsy with spastic quadriparesis                                                                            CVI, estotropia, nystagmus, blepharoptosis, scoliosis, restless sleeper, not toiled trained
                                                                                                                                                    p.D845Rfs\*40                                                                                                                                                                                                                                                                                                                                                             

  G-tube                                                                    Periventricular leukomalacia, thin CC, Subependymal cysts                                                                                                                                                                                                                                                                                                                                                                                         

  Patient 3                                                                                           5 yr                                 M        c.1881delG\                 De novo                \+             \+ (IQ \<50)    UKN                      UKN                                                        UKN        \+           \+      −                          −                   Ataxic gait, autism, epileptic activity on EEG                                                                       Sagittal craniosynostosis, cochlear nerve dysfunction, hypermobile joints
                                                                                                                                                    p.Q627Hfs\*105                                                                                                                                                                                                                                                                                                                                                            

  Patient 4                                                                                           4 yr                                 F        c.1122dupC\                 De novo                \+                  \+         20 mo                    Single words                                               91         \+           −       \+                         \+                  Wide based gait, nystagmus                                                                                           Affectionate
                                                                                                                                                    p.G375Rfs\*3                                                                                                                                                                                                                                                                                                                                                              

  Feeding difficulties                                                        Small CC, loss of posterior ventricular white matter                                                                                                                                                                                                                                                                                                                                                                                            

  Patient 5                                                                                           9 yr                                 M        c.3809delA\                 De novo                \+                  \+         4 yr 9 mo                No verbal speech (had a maximum of 2--3 words at 2 yr    75--90       \+           \+      \+                         \+                  Ataxia, intermittent nystagmus, ptosis, mildly self-injurious and intermittent behavior problems, disrupted sleep,   Left central macular dystrophy, isolated complex IV deficiency on muscle biopsy (24% of control)
                                                                                                                                                    p.Q1270Rfs\*75                                                                                                                                                                                                                                                                                                                                                            

  FTT                                                                              Hypomyelination, thin CC, small brain stem                                                                                                                                                                                                                                                                                                                                                                                                 

  Patient 6                                                                                           5 yr                                 M        c.2373\_ 2374delTG\         De novo                \+                  \+         2 yr                     Two word sentences                                         50         \+           \+      −                          \+                  Ataxia, seizures, impulsive                                                                                          Mild joint laxity
                                                                                                                                                    p.C791Wfs\*57                                                                                                                                                                                                                                                                                                                                                             

  Prominent CSF space---small arachnoid cyst vs. abnl cisterna magna                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Patient 7                                                                                           16 yr                                F        c.1480 A\>T\                De novo                \+                  \+         UKN                      No verbal speech                                         50--75        −           \+      \+                         \+                  Autism, aggressive, self-injurious, strabismus, developmental regression, increased pain tolerance                   Club foot, pes cavus
                                                                                                                                                    p.K494Ter                                                                                                                                                                                                                                                                                                                                                                 

  Feeding difficulties, short stature                                   Demylenation involving subcortical U fibers, retrocerebellar cyst                                                                                                                                                                                                                                                                                                                                                                                     

  Totals                                                                                                                                                                                               7/7                 6/6                                                                                                       6/7         6/7      5/7                        5/7                 5/7 Ataxic, 2/7 autism                                                                                               
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

OFC, occipital frontal circumference; M, male; F, female; UKN, unknown; N/A, not applicable; ASD, atrial septal defect; CVI, cortical visual impairment; EEG, electroencephalogram; CC, corpus callosum; FTT, failure to thrive; CSF, cerebrospinal fluid.

In addition to the neurobehavioral features, there are other clinical manifestations. Six patients have dysmorphic facial features including bitemporal hollowing, brachycephaly, plagiocephaly, short nose, narrow mouth, highly arched palate, tented upper lip, and high, prominent forehead with prominent glabella ([Fig. 1](#YANGMCS000562F1){ref-type="fig"}). Five patients had a history of growth problems including short stature or failure to thrive and feeding difficulties. Two of the patients have joint laxity. Five patients have ophthalmologic problems, including one with cupped optic disks with unilateral central macular dystrophy and nystagmus, one with nystagmus only, two with strabismus only, and one with nystagmus along with strabismus and cortical visual impairment.

![Facial characteristics of individuals with *AHDC1* variants including a high, broad prominent forehead, hypertelorism, depressed nasal bridge, and thin upper lip.](YangMCS000562_F1){#YANGMCS000562F1}

DISCUSSION {#s3}
==========

Seven proband-parent trios with de novo *AHDC1* variants were identified through whole-exome sequencing on 2157 cases with ID or developmental delay. The seven patients from unrelated families with a similar clinical phenotype of severe intellectual disability or neurodevelopmental delay, dysmorphic features, and problems with feeding and growth were all found to be heterozygous for novel de novo truncating variants in *AHDC1*. We report six novel predicted deleterious variants and one recurrent variant, (p.Cys791Trpfs\*57), which was previously reported in two patients by Xia et al. ([@YANGMCS000562C34]). Xia et al. has proposed that *AHDC1-*associated ID is due to a dominant-negative mechanism given the autosomal-dominant inheritance and the single coding exon of this gene. However, a de novo balanced translocation with a breakpoint in *AHDC1* intron 1 that disrupts the 5′UTR of *AHDC1* has been identified in a 5-yr-old male patient with developmental delay and ID ([@YANGMCS000562C23]). *AHDC1* expression in lymphoblastoid cells was found to be reduced to 50% of wild-type levels, supporting haploinsufficiency as disease mechanism for *AHDC1* mutations ([@YANGMCS000562C23]). Additionally, several large CNV deletions that include the *AHDC1* gene have been described in pediatric patients with developmental delay and intellectual disability ([@YANGMCS000562C12]; [@YANGMCS000562C8]; [@YANGMCS000562C7]). However, due to the large size of the deletions, it is uncertain whether *AHDC1* is the only gene contributing to the neurodevelopmental phenotype.

*AHDC1* consists of seven exons with only one coding exon (exon 6). Five 5′ noncoding exons and one 3′ noncoding exon flank the coding exon. *AHDC1* encodes the 1603 amino acid protein AT-hook DNA-binding motif-containing protein 1, which likely binds DNA ([Fig. 2](#YANGMCS000562F2){ref-type="fig"}; [@YANGMCS000562C25]). By aligning human AHDC1 to other protein orthologs, two conserved regions have been reported in AHDC1 ([@YANGMCS000562C34]). The first conserved region has two AT-hook motifs located at amino acids 396--408 and 544--556. AT-hook motifs are known as auxiliary protein motifs that cooperate with other DNA-binding activities and facilitate DNA structure changes ([@YANGMCS000562C2]). The AT-hook binding domain in MECP2, the gene mutated in Rett syndrome, plays an important role in chromatin organization ([@YANGMCS000562C3]; [@YANGMCS000562C35]). The second conserved region near the carboxyl terminus contains a carboxy-terminal PDZ binding domain consensus sequence that interacts with PDZ domain proteins ([@YANGMCS000562C29]). PDZ domain proteins regulate multiple biological processes such as transport of electrolyte and fluid ([@YANGMCS000562C28]), ion channel signaling, and signal transduction systems by recognizing short amino acid motifs at the carboxyl termini of target proteins ([@YANGMCS000562C13]).

![*AHDC1* gene organization and distribution of truncating mutations. *AHDC1* consists of seven exons with only one coding (exon 6). Three mutations above the schematic protein were reported by [@YANGMCS000562C34]. Six mutations below the schematic protein are novel mutations reported in this study. The mutation in the box reported by Xia et al. was found in one of our probands.](YangMCS000562_F2){#YANGMCS000562F2}

The in vivo targets for AHDC1 binding are largely unknown. However, in vitro assays demonstrate that AHDC1 interacts with a number of other nuclear proteins ([@YANGMCS000562C6]), influencing transcriptional and epigenetic regulation during development ([@YANGMCS000562C16]; [@YANGMCS000562C32]), receptors in neurite growth, neuronal adhesion, and axonogenesis ([@YANGMCS000562C20]), and transporters for specific neuron proteins ([@YANGMCS000562C5]). *AHDC1* is expressed throughout the brain ([@YANGMCS000562C22]; [@YANGMCS000562C31]). In the mouse, *Ahdc1* is expressed at embryonic day E11.5 and E16.5 in the developing brain ([@YANGMCS000562C23]), suggesting that *AHDC1* may be involved in early brain development.

Four of our de novo *AHDC1* variants and three previously reported variants ([@YANGMCS000562C34]) are predicted to cause protein truncation beyond the AT-hook motifs and to eliminate the PDZ binding domain consensus sequence. The other two remaining de novo *AHDC1* variants (p.Lys494Ter and p.Gly375Argfs\*3) lead to an even earlier stop of translation thus destroying both of the conserved regions. As these truncating variants are all located in the single coding exon of *AHDC1*, they may not result in nonsense mediated mRNA decay ([@YANGMCS000562C27]). Although we did not conduct expression studies in our cohort, based on these observations, we speculate that *AHDC1* variants may interrupt protein translation, leading to truncated proteins missing the functional domains, possibly disrupting the interaction with other proteins, such as PDZ domain proteins important to brain development and function. The phenotype in all seven patients we report is dominated by neurobehavioral manifestations including ID, autism spectrum disorder, sleep disturbances, gross motor delays, and ataxia, but also includes facial dysmorphism. Our series expands the phenotype of *AHDC1* disorders to include behavioral phenotypes of aggression, self-injurious behavior. Other medical features include problems with growth, epilepsy, nystagmus, omphalocele, and clubfoot.

WES has become an important diagnostic tool to evaluate patients with developmental delay and ID, especially in patients with nonspecific clinical features. Our study demonstrates that truncating de novo variants in *AHDC1* are a rare cause of severe ID and are associated with feeding difficulties and problems with growth, and a neurobehavioral phenotype is emerging that includes challenging behaviors such as self-injury, aggression, autism, ataxia, and disordered sleep. Variants in *AHDC1* should be further investigated in patients with this neurobehavioral profile.

METHODS {#s4}
=======

Whole-Exome Sequencing {#s4a}
----------------------

Genomic DNA from whole blood from the affected children and their parents was extracted. Exome sequencing was performed on exon targets isolated by capture using the Agilent SureSelect Human All Exon V4 (50 Mb) kit (Agilent Technologies). One microgram of DNA from blood specimen was sheared into 350- to 400-bp fragments, which were then repaired, ligated to adaptors, and purified for subsequent PCR amplification. Amplified products were then captured by biotinylated RNA library baits in solution following the manufacturer\'s instructions. Bound DNA was isolated with streptavidin-coated beads and re-amplified. The final isolated products were sequenced using the Illumina HiSeq 2000/2500 sequencing system with 100-bp paired-end reads (Illumina). DNA sequence was mapped to the published human genome build UCSC hg19/GRCh37 reference sequence. Targeted coding exons and splice junctions of known protein-coding RefSeq genes were assessed for average depth of coverage with a minimum depth of 10× required for inclusion in downstream analysis. Local realignment around insertion--deletion sites was performed using the Genome Analysis Toolkit v1.6. ([@YANGMCS000562C9]). Variant calls were generated simultaneously on all sequenced family members using SAMtools v0.1.18. ([@YANGMCS000562C15]). All coding exons and surrounding intron/exon boundaries were analyzed. Automated filtering removed common sequence changes (defined as \>10% frequency present in 1000 Genomes database) and additional filtering focused on variants with an allele frequency \<1%. The targeted coding exons and splice junctions of the known protein-coding RefSeq genes were assessed for the average depth of coverage and data quality threshold values. Whole-exome sequence data for all sequenced family members were analyzed using GeneDx\'s XomeAnalyzer (a variant annotation, filtering, and viewing interface for WES data), which includes nucleotide and amino acid annotations, population frequencies (NHLBI Exome Variant Server and 1000 Genomes databases), in silico prediction tools, amino acid conservation scores, and mutation references. Variants were filtered based on inheritance patterns, gene lists of interest, phenotypes, and population frequencies, as appropriate. Resources including the Human Gene Mutation Database (HGMD), 1000 Genomes database, NHLBI Exome Variant Server, OMIM, PubMed and ClinVar were used to evaluate genes and detected sequence changes of interest. The general assertion criteria for variant classification are publicly available on the GeneDx ClinVar submission page (<http://www.ncbi.nlm.nih.gov/clinvar/submitters/26957/>). Additional searches were performed using specific gene lists related to clinical features of the patients. Identified sequence changes of interest were confirmed in all family members by conventional di-deoxy DNA sequence analysis using an ABI 3730 (Life Technologies) and standard protocols with a new DNA preparation.
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